文献速递前列腺癌

活检格里森分级分组1的前列腺癌患者的死亡风险

Mortality Risk for Patients with Biopsy Gleason Grade Group 1 Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-07-02

该研究纳入德国汉堡一家大学医院队列中10228例经活检诊断为格里森分级分组1的前列腺癌患者,分析临床因素与根治性前列腺切除术后不良病理及死亡风险的关联。结果显示,无论活检方式,阳性活检百分比>50%和PSA>20 ng/ml与不良病理及早期PSA失败风险升高显著相关。

要点

  • 在系统性活检组中,阳性活检百分比>50%和PSA>20 ng/ml与前列腺癌特异性死亡风险升高相关(aHR分别为2.56和3.71)。
  • 在系统性活检组中,阳性活检百分比>50%和PSA>20 ng/ml也与全因死亡风险升高相关(aHR分别为1.47和2.00)。
  • 作者认为,对阳性活检百分比>50%或PSA>20 ng/ml的格里森分级分组1患者维持癌症分类并考虑再次活检可能降低该亚组的死亡风险。

核心结论

  • 对活检格里森分级分组1且阳性活检百分比>50%或PSA>20 ng/ml的患者维持癌症分类并考虑再次活检,可能降低该亚组的死亡风险。

研究设计与样本

  • 研究为德国汉堡一家大学医院的队列研究,纳入10228例经活检诊断为格里森分级分组1前列腺癌的患者,其中经直肠超声引导系统性活检9248例,联合活检980例。

主要发现

  • 在系统性活检组中,阳性活检百分比>50%和PSA>20 ng/ml与不良病理风险升高相关(aOR分别为1.71和3.49),在联合活检组中亦相关(aOR分别为1.81和2.82)。
  • 在系统性活检组中,阳性活检百分比>50%和PSA>20 ng/ml与早期PSA失败风险升高相关(aHR分别为1.54和4.37),在联合活检组中亦相关(aHR分别为2.88和7.81)。
  • 在系统性活检组中,阳性活检百分比>50%和PSA>20 ng/ml与前列腺癌特异性死亡风险升高相关(aHR分别为2.56和3.71,均p≤0.04)。
  • 在系统性活检组中,阳性活检百分比>50%和PSA>20 ng/ml与全因死亡风险升高相关(aHR分别为1.47和2.00,均p≤0.04)。

临床怎么用

  • 作者认为,对格里森分级分组1且阳性活检百分比>50%或PSA>20 ng/ml的患者维持癌症分类并考虑再次活检。
  • 原文未据此给出针对联合活检组的独立推荐。

局限性

  • 该研究受单机构队列设计限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: We investigated the association of clinical factors at presentation with the presence of unsampled high-risk prostate cancer (PC) and PC-specific mortality (PCSM) and all-cause mortality (ACM) following radical prostatectomy in patients with biopsy Gleason Grade Group (GGG) 1 PC. METHODS: The study population comprised 10228 patients treated for GGG1 PC diagnosed via transrectal ultrasound (TRUS)-guided systematic biopsy (SBx; n = 9248) or combined biopsy (CBx; SBx + TRUS/magnetic resonance image [MRI] fusion biopsy; n = 980) from a cohort study at a university hospital in Hamburg, Germany. We used logistic, Fine and Grays, and Cox multivariable regression methods to calculate the adjusted odds ratio (aOR) of adverse pathology and adjusted hazard ratios (aHRs) for early prostate-specific antigen (PSA) failure (≤18 mo), PCSM, and ACM in relation to each clinical factor. KEY FINDINGS AND LIMITATIONS: Irrespective of biopsy approach, percent positive biopsies (PPB) >50% and PSA >20 ng/ml were significantly associated with higher risk of adverse pathology (SBx: aOR 1.71 and 3.49; CBx: aOR 1.81 and 2.82, respectively) and early PSA failure (SBx: aHR 1.54 and 4.37; CBx: aHR 2.88 and 7.81, respectively). PPB >50% and PSA >20 ng/ml were also associated with higher risk of PCSM (aHRs 2.56 and 3.71) and ACM (aHRs 1.47 and 2.00) in the SBx group (all p ≤ 0.04). The study is limited by the single-institution cohort design. CONCLUSION AND CLINICAL IMPLICATION: Maintaining the "cancer" classification for patients with GGG1 and either PPB >50% or PSA>20 ng/ml and considering rebiopsy to identify unsampled high-grade disease may minimize the risk of mortality for this subgroup. PATIENT SUMMARY: For patients undergoing non-targeted prostate biopsy, approximately 1 in 12 with a biopsy result of grade group 1 prostate cancer may have more aggressive cancer than the result suggests. A very high PSA (prostate-specific antigen) level (>20 ng/ml) or the presence of grade group 1 cancer in more than 50% of the biopsy samples can identify patients at risk.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tilki D, Chen MH, Huland H, et al. Mortality Risk for Patients with Biopsy Gleason Grade Group 1 Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38960834. doi:10.1016/j.euo.2024.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。